Results of the EXAMINE cardiovascular (CV) safety outcomes trial testing Nesina/Vipidia (alogliptin), from Takeda, show alogliptin does not increase CV...
Vipidia is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).
Takeda Pharmaceutical Company Limited announced that a post hoc analysis of data from the global EXAMINE (EXamination of CArdiovascular OutcoMes:...
Takeda has re-filed applications for Nesina (alogliptin) as a monotherapy and alogliptin plus pioglitazone at the FDA following a Complete...